Effect of Patient Financial Incentives on Statin Adherence and Lipid Control
Author(s) -
Iwan Barankay,
Peter P. Reese,
Mary Putt,
Louise B. Russell,
George Loewenstein,
David Pagnotti,
Jiali Yan,
Jingsan Zhu,
Ryan McGilloway,
Troyen A. Brennan,
Darra D. Finnerty,
Karen Hoffer,
Sakshum Chadha,
Kevin G. Volpp
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.19429
Subject(s) - psychological intervention , medicine , incentive , randomized controlled trial , statin , physical therapy , population , environmental health , nursing , economics , microeconomics
Key Points Question Can daily financial incentives for medication adherence induce lasting habits for statin adherence and sustained reductions in low-density lipoprotein cholesterol (LDL-C) levels even after financial incentives are discontinued? Findings In a randomized clinical trial of individuals at elevated risk of cardiovascular disease and with suboptimal cholesterol levels and imperfect adherence, participants in the intervention groups received financial incentives for statin adherence for 6 months. Measured adherence was better among individuals receiving financial incentives, but the change in LDL-C level from baseline to 12 months, the primary outcome, did not differ between intervention and control groups. Meaning Measured improvements in adherence after financial incentives did not translate into improved LDL-C levels.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom